Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- NIH, D.C. Health Department To Launch HIV Treatment Study
- An Action Plan For Zimbabwe
- Racial HIV Disparities Are An Indictment Of The US Response To The Epidemic
- Indonesia Provides Three Provinces With Funding To Heighten HIV/AIDS Efforts
- IPS Examines How Funding Cuts Might Affect HIV/AIDS Treatment Programs Worldwide
- Predicting Fatal Fungal Infections
- Genetic, Geographic Data Deliver Clear Picture Of HIV Progress, Explaining HIV Spread In Central And East Africa
- Senate Fiscal Year 2010 Spending Bill Excludes Abstinence-Only Education Funding, Needle Exchange Language
- Condom Distribution Program In Los Angeles County Jail Might Be Expanded
- Washington Post Examines HIV/AIDS Rights, Responsibilities Questions
Prescription AIDS Drugs
Contact Us
NanoViricides Platform Enables Rapid Development Of Robust Nanomedicines Against Influenza And HIV
July 20th, 2010
NanoViricides, Inc. (OTC BB: NNVC.OB) (the “Company”), announced that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.
Dr. Diwan described the salient features of nanoviricides technology. “Viruses can be fooled,” he said, adding, “We use their own smarts to attack them. The site at which a virus binds to the cell surface never changes, no matter how much the virus itself changes. We mimic this site, and the cell surface, so the virus particle can bind to the nanoviricide thinking it is binding to a cell. We anticipate very little escape mutation problem, if we do this successfully.”
He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (influenza virus challenge administered to mice. These studies have been repeated and the Company has performed SAR (structure-activity-relationship) studies to develop the best drug candidates against influenza. “Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”
He also described that HIVCide™ was found to be more than twenty-five times (25X or 2,500%) superior to the entire three drug HAART cocktail in a standard SCID-Hu mouse model study. The mice were treated with only 150 mg/kg of nanoviricides and this treatment both led to improvement in double-positive CD4+/CD8+ T cells and reduction in HIV-1 viral load that was equal to or slightly better than that in HAART-treated mice. The HAART treated mice received a total drug load of 4,200 mg/kg, indicating superior results with HIVCide. Moreover, HAART cocktail caused significant toxic effects, whereas the nanoviricides produced no clinical adverse signs in this study.
Dr. Diwan also described the high efficacy of EKCCide™ in a rabbit model, which caused complete clinical resolution of adenoviral kerato-conjunctivitis in as little as 2.5 days. The Company is not aware of any other drug candidate that had shown clinical improvement in this disease in any earlier animal studies.
Dr. Diwan also described the Social Responsibility programs of the Company, which include drug development against Dengue viruses, Rabies virus, as well as Biodefense programs that include broad-spectrum drug development against hemorrhagic viruses including Ebola/Marburg, and the ADIF™ “Accurate Drug In Field” technology against novel and emerging viruses.
“The Company has continued its development of FluCide, HIVCide, and the ocular nanoviricide eye drops, which are programs of very high commercial interest,” said Dr. Eugene Seymour, MD, MPH, commenting further that, “We continue to invest minimal amounts of Company funds in the Social Responsibility and Biodefense projects, and we will require public funding for the same.”
About NanoBusiness2009
This is the 8th annual conference on the business of nanotechnology organized by the NanoBusiness Alliance. The NanoBusiness Alliance mission is to create a collective voice for the advancing nanotechnology industry and develop a range of initiatives to support the nanotechnology business community.
Source
NanoViricides
View drug information on Tamiflu capsule.
Related posts:
- Cytheris Announces Publication Of IL-7 Primate Study Showing Rapid And Massive T Cell Homing To The Gut Cytheris SA, a clinical stage biopharmaceutical company focused on research...
- New Advances On The Long Road To The Development Of An AIDS Vaccine AIDS Vaccine Day, May 18, marks the occasion in 1997...
- WHO Recommends Against Using Homeopathic Treatments For HIV, TB, Malaria, Influenza, Infant Diarrhea Patient / Public: Health Professional: Article Opinions: 0 posts...
- Focusing On The HIV Virus: £1.7M Award To Develop Nanotechnology For Use In Health Care Scientists at the University of Liverpool have been awarded £1.7...
- How Key Protein Keeps Chronic Infection In Check Why is the immune system able to fight off some...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.